active long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr Angela Cenci Nilsson of Lund University in Sweden is listed as the/a researcher for Anavex 2-73 use in Parkinson's. This cites her early research for a thesis, but I can't find the follow on research the MJFF is funding. Anyone have more information on the Parkinson's study involving 2-73?
https://portal.research.lu.se/en/publications/endogenous-and-treatment-induced-neuroplasticity-in-mouse-models-
Lacey, Falconer, Nidan, its positive that this cite allows us to share medical and curbside knowledge that sometimes comes from little trial "n". Meanwhile millions suffer and die while formal drug development follows the slow gathering of statistics and presentation before world agencies! We understand the need for safety and efficacy, but those with approval authority are by in large state salaried bureaucrats who are not prone to "reach for the stars". I fully appreciate operating within safe guidelines being an Air Force Flight Safety Officer for many years, but I also knew that lives depended on rapid mission accomplishment in "life or death" contingencies. So what I am leading to is, with millions ww facing disease degradation and death, the medical establishment and drug approval authorities need to go to war with the enemy and not rely on job safety and commercial politics. We as a country lose more of our children, parents and grandparent each year than in all the military conflicts on the horizon. If we forced all of our defense industry in time of conflict to operate at peacetime development speed, we would not be a free nation today. The medical drug industry is at war every day and countless are falling each day ........sound the bugle!!
The MM are playing with the stock until EMA submission or partnership with a Pharma!
Hosai.....very sound logic and you wonder why the FDA and the US Government are not doing every thing possible from a scientific and economic perspective to conquer Alzheimers! It is a sure death sentence for "everybody" who contracts it and is a tremendous emotional and money drain for the families of the patients. You would think that a cause which kills nearly or more than 1,000,000 of us a year would be one of our country's top priorities. Yet politics and money have slowed our progress. Cancer has coalesced our medical focus, but maybe its Alzheimers attack on the older end of humanity that have dulled our efforts. Those who have a loved one with the disease would want you to listen!!!
Leaving Alzheimers progress as a market decision is really a crime against humanity!
BB.....I agree with you....Merck needs another "Keytuda" in neurology.
Redshoulder....thanks for the EMA timeline. It is evident that at an early time in drug approval schedule a big Pharma partner must join in the process to outline the marketing, distribution and sales plan for after the drug is approved. This is a very important assessment for the EMA to evaluate for any drug that will be approved for treating Europe's 6-7 million Alzheimer's patients. My estimate is the big brother partner will have to be announced very soon.
Plex....with all due respect....neither of us have any proof either way! Still at the end of the trading day the stock is climbing rapidly with high volume then they blumt its ascent. Only the MM knows!
It sure looks like manipulation when the stock price is moved from $6.5 to $7.1 and back down to $6.8 in 2 hrs...the hand of the MM!
Power....let's see if the new legislation will prioritize Alzheimer's clinical research similar to the governmental cancer emphasis over the last few years. To a degree the FDA appears conscious of the concern for dementia drug success with the pushing of the MAB's. let's see if there is some impetus for drugs like 2-73!
Todays PR is positive news to offset the recent negative decision by the EMA about Leqembi. They have a safe alternative in 2-73 which they can act on Q4 of this year which will give hope to some 6 million Alzheimer's suffers in the EU. FDA and partners take note!
https://www.investors.com/news/technology/biogen-stock-alzheimers-treatment-leqembi-europe/?src=A00220
Flew C-141s out of Charleston Leo....we must have talked at times in those 37 years.
The rest of the market appears "soft", but we're up on nearly 800,000 shares traded!
Rare form, Ziggy. Everybody else is celebrating the climb today!
MJFF is still studying 2-73, but we haven't had an update in a while....anyone have a contact in the MJFF that they can poll?
https://www.michaeljfox.org/grant/evaluation-anavex2-73-blarcamesine-participants-parkinsons-disease
Cres...thank you for "rethinking" my logic!
SAVA up 28% today on a "rosy" outlook by their new President Barry looking at the "possible" clinical results in the next year! Shows that that there is "hope" in the Alzheimers market, but not a lot drug knowledge! For SAVA that has a drug which is surrounded by considerable controversy, to have more than twice the market value of AVXL is really illogical! The sports world has its coaches that can talk "a good game"....well so does the pharmaceutical world!
https://finance.yahoo.com/news/why-cassava-sciences-stock-skyrocketing-152733308.html
Power...spot on, today the MM and "high frequency trading" are keeping what appeared to be another good day in check. Meanwhile SAVA and ANVS are trading at twice our share price. Both of them are struggling with their clinical progress and they aren't nearly as close to new drug submission as AVXL. The market is not controlled with honest trading, but rather insider play! Time to get a "heavy weight" partner!
Xena.....very informative video, although the young narrator verges on "anti-capitalism" or citing the very rich taking advantage of capitalism! But, the main point that I agree with him is, that Larry Fink and Blackrock are exploiting the control of "infrastructure" to gain wealth. While the commentator gave examples of physical "infrastructure", I believe Fink and Blackrock are after medical "infrastructure" as well. At this moment there is great wealth in medicine for unmet health needs like Alzheimer's. Yahoo Finance will show that Fink/Blackrock is the 3rd largest institutional investor in Biogen(14 mil shares), the 2nd in Lilly(65 mil shares) and the 2nd in Anavex(6.6 mil shares)! There are those who will say that Blackrock is there thru Index funds, but the video shows that Fink and others are much more intentional when it comes to capturing the untold $Millions in "Medical Infrastructure". We will see how this plays out, but don't count out that Fink has a finger in the pie!
Ziggy, I'm sorry, your pessimism has been present well before the end of this week...I must give credit were credit is due! Have a nice weekend....I don't mean to spoil it before it has begun.
Ziggy....such pessimism at the end of the week!
Xena....Talk about rigged systems.....how can SAVA and ANVS remain at a $10 share price with controversy over their one drug and Anavex with 2 drugs doing well in trials for Alzheimer's, Parkinson's, Schizophrenia, Rett Syndrome with several more coming on soon remain at $4. And on the verge of an MMA with the EMA shortly. And financially viable at $139 million. It appears that market forces play their own game and it will take news of a scientific paper or the announcement of the EMA submission to get them out of our wallets! Thanks for you stabilizing wisdom on this board!
Plex....glad to see at least an ounce of optimism is left. This race is like the 10,000 meters, the winner isn't known until the final home stretch! Let's root Anavex home.
Xena.....what a service to Anavex holders....it highlights that the stockmarket is not solely the realm of the country's ownership in public businesses, but a mechanism for shady elements to separate the public from their hard earned money. Just where is the SEC and the Justice Department in insuring honesty at the highest levels of our national financial institutions!
Plex...my supposition is that our drug would have to be approved before prescribed prophylactically!!!!!
Agree wholeheartedly......Anavex prophylactically started at 40!!!!
Biogen and Eisai are tapping into a big market before Lilly gets into the market. At its cost and medical complexity, its marketability maybe somewhat limited.
https://finance.yahoo.com/news/eisai-biogen-launch-leqembi-alzheimer-101302117.html
IR, you've named the main culprits, but the ''big guys" have benefitted to a great degree from the lower prices that the other culprits have affected. Blackrock's CEO is one of the great influencers in the stockmarket and certainly abets practices that afford him larger positions in publicly held companies.
IR...maybe we don't agree on the players and their association, but we should agree on Blackrock, StateStreet and Vanguard benefiting from the effect of "high frequency trading".
Agree with you IR....the MM's with "high frequency trading" are driving the price down at the bequest of the "big boys" prior tp Wainright news tomorrow. Also note the level of negative posts today after several good days of trading. This episode in our stock's trading has happen so many times before! Through it all the "big boys" have continued to accumulate...predict we will be well over 40% of institutional ownership at the next reporting. The "longs" will be patient until public review, EMA/FDA submission and/or partnership announcement. Hang tough longs!!!!
Powerwalker....agree completely that ADL in early Alzheimer's patients is a very difficult area to measure as Falconer has discussed. It appears that the FDA thinks so also. Brain size reduction is far more indicative of the disease implication! Although, it too may be hard to determine in Alzheimer's early stages.
New test will possibly detect Parkinson's many years before symptoms....AVXL 2-73 with its mild/no side effects may be the drug to use prophylactically against this disease! Another arrow in the quiver!
https://www.foxnews.com/health/ai-blood-test-could-detect-parkinsons-disease-7-years-before-symptoms-particularly-promising
Plex.....according to the agenda, Anavex will have an hour and a half for the presentation and questions, which is positive!
They had their chance and muffed it years ago!
Triple Witching drove AVXL to almost 6Million shares? None of our competitors BIIB, SAVA, ANVS had anywhere near that volume! Reasons please.
My personal guess as to whom we might partner with is Merck. Merck is a huge multinational pharmaceutical established in Germany in 1668 (that's right over 350 years ago). Merck in America is primarily into oncology and their chief drug is keytruda which is used by itself and in combination with other drugs in cancers with many applications. Merck USA has one drug for schizophrenia, but may be attracted by 2-73's possible multiple uses. Dr Missling will be very familiar with Merck. In any case, a good possibility!
A sad commentary on the early onset of Alzheimer's in Michael Irvin's wife. Every reason for the progress our drug as hope for them and many other couples fighting this terrible disease. Michael has his hope in God's providence, and we hope that God works thru Anavex and other fruitful research!
https://www.foxnews.com/sports/cowboys-legend-michael-irvin-reveals-wife-58-has-early-onset-alzheimers
Cornflakes.....you seem to be at the end of your patience. At least you are using acronyms to keep it clean. Maybe its worth your time and money for a trip to NY!
This ZACKS article continues the pumping of "amyloid-beta drugs that the FDA is saying have an acceptable ratio of "benefit to adverse effect ratio". Two other companies are noted including SAVA. With Anavex on the verge of EMA application for 2-73, one would think ZACKS would plug it, but then again it is an example of them(Biogen/Eisai and Lilly) more than likely putting adverse pressure on the most dangerous competition!
https://finance.yahoo.com/news/alzheimers-focus-fda-panel-endorses-152100818.html
Good advice Falconer.....my comment with about 8 years invested in the stock and over 2000 posts on the board is that we are subject to the stock trading mechanics (+/-) to a much greater degree than the true course of medical science. That is a stark realization in watching development work of small biotechs versus the marketing politics of big pharmas. The market protection is only too evident with the big drug companies and the FDA in concert with this. This was so apparent during the COVID period with the rapid development and approval of vaccines and the disregard of "adverse effects"! To watch our stock move these days, with millions of shares traded and the value of the stock pushed down on no adverse news, has been a deep disappointment to us as investors....but more so to the many who look to the promise of relief from deadly diseases. I'm not ignorant of the profit motive in a capitalist economy, but just as the defense sector of our government should be driven by national threats, the medical (FDA) sector should driven by health threats to the American population!
Institutional holding continues to rise with State Street, BlackRock and Vanguard leading close to the 40% level. You know the the MM are holding the price down to enable that and seeing the "big guys" buy days. These "big guys" continue to add to their shares of AVXL. Look for a partner buy in soon. Anavex will not proceed toward NDA without the production/marketing/distribution infrastructure beinging in-place before drug approval and they are too small to do it all themselves!